

CLAIMS

We claim:

5

10

15

20

25

- 1. An isolated DNA selected from the group consisting of:
- (a) a DNA encoding a protein having an amino acid sequence as set forth in SEQ ID NO:10, wherein the protein has an amino terminus selected from the group consisting of an amino acid between amino acid 1 and amino acid 139, inclusive, and a carboxy terminus selected from the group consisting an amino acid between amino acid 290 and amino acid 294, inclusive;
- (b) a DNA encoding a protein having an amino acid sequence as set forth in SEQ ID NO:12, wherein the protein has an amino terminus selected from the group consisting of an amino acid between amino acid 1 and amino acid 162, inclusive, and a carboxy terminus selected from the group consisting of an amino acid between amino acid 313 and amino acid 317, inclusive;
- (c) DNA molecules capable of hybridization to the DNA of (a) or (b) under stringent conditions, and which encode biologically active RANKL; and
- (d) DNA molecules encoding fragments of proteins encoded by the DNA of (a), (b) or (c).
- 2. The isolated DNA of claim 1, which encods a RANKL polypeptide that is at least about 70% identical in amino acid sequence to the native form of RANKL as set forth in SEQ ID Nos:10 and 12.
 - 3. The isolated DNA of claim 1, which encodes a soluble RANKL polypeptide.
 - 4. The isolated DNA of claim 2, which encodes a soluble RANKL polypeptide.
- 5. An isolated DNA encoding a soluble RANKL, selected from the group consisting of:
- 30 (a) a DNA encoding a protein having an amino acid sequence as set forth in SEQ ID NO:10, wherein the protein has an amino terminus selected from the group consisting of an amino acid between amino acid 48 and amino acid 139, inclusive, and a carboxy terminus selected from the group consisting an amino acid between amino acid 290 and amino acid 294, inclusive;
- 35 (b) a DNA encoding a protein having an amino acid sequence as set forth in SEQ ID NO:12, wherein the protein has an amino terminus selected from the group consisting of an amino acid between amino acid 69 and amino acid 162, inclusive, and a carboxy terminus

20

4.

5.

5

10

15

IMMUNEX CORPORATION Docket No. 2852-A selected from the group consisting of an amino acid between amino acid 313 and amino acid 317, inclusive;

- (c) DNA molecules capable of hybridization to the DNA of (a) or (b) under stringent conditions, and which encode biologically active RANKL; and
- (d) DNA molecules encoding fragments of proteins encoded by the DNA of (a), (b) or (c).
- The isolated DNA of claim 5, which further comprises a DNA encoding a polypeptide selected from the gourp consisting of an immunoglobulin Fc domain, an immunoglobulin Fc mutein, a FLAGTM tag, a peptide comprising at least about 6 His residues, a leucine zipper, and combinations thereof.
 - 7. A recombinant expression vector comprising a DNA sequence according to claim 1.
 - 8. A recombinant expression vector comprising a DNA sequence according to claim 2.
- 9. A recombinant expression vector comprising a DNA sequence according to claim 3.
 - 10. A recombinant expression vector comprising a DNA sequence according to claim
 - 11. A recombinant expression vector comprising a DNA sequence according to claim
- 12. A recombinant expression vector comprising a DNA sequence according to claim 6.
- A host cell transformed or transfected with an expression vector according to 30 claim 7.
 - A host cell transformed or transfected with an expression vector according to claim 8.
- 15. A host cell transformed or transfected with an expression vector according to 35 claim 9.

15

20

25

30

5

IMMUNEX CORPORATION

Docket No. 2852-A

- 16. A host cell transformed or transfected with an expression vector according to claim 10.
- 17. A host cell transformed or transfected with an expression vector according to claim 11.
- 18. A host cell transformed or transfected with an expression vector according to claim 12.
- 19. A process for preparing a RANKL protein, comprising culturing a host cell according to claim 13 under conditions promoting expression and recovering the RANKL.
 - 20. A process for preparing a RANKL protein, comprising culturing a host cell according to claim 14 under conditions promoting expression and recovering the RANKL.
 - 21. A process for preparing a RANKL protein, comprising culturing a host cell according to claim 15 under conditions promoting expression and recovering the RANKL.
 - 22. A process for preparing a RANKL protein, comprising culturing a host cell according to claim 16 under conditions promoting expression and recovering the RANKL.
 - 23. A process for preparing a RANKL protein, comprising culturing a host cell according to claim 17 under conditions promoting expression and recovering the RANKL.
 - 24. A process for preparing a RANKL protein, comprising culturing a host cell according to claim 18 under conditions promoting expression and recovering the RANKL.
 - 25. An isolated DNA selected from the group consisting of oligonucleotides of at least about 17 nucleotides in length, oligonucleotides of at least about 25 nucleotides in length, and oligonucleotides of at least about 30 nucleotides in length, which is a fragment of the DNA of SEQ ID NO:10 or SEQ ID NO:12.
 - 26. An isolated RANKL polypeptide selected from the group consisting of:
- (a) a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 11, wherein the polypeptide has an amino terminus selected from the group consisting of an amino acid between amino acid 1 and amino acid 139, inclusive, and a carboxy terminus selected from the group consisting of and amino acid between amino acid 290 and 294, inclusive;

5

10

15

20

30

35

IMMUNEX CORPORATION

Docket No. 2852-A

- (b) a a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 13, wherein the polypeptide has an amino terminus selected from the group consisting of an amino acid between amino acid 1 and amino acid 162, inclusive, and a carboxy terminus selected from the group consisting of and amino acid between amino acid 313 and 317, inclusive;
- (c) a RANKL polypeptide encoded by a DNA capable of hybridization to a DNA encoding the protein of (a) or (b) under stringent conditions, and which is biologically active; and
 - (d) fragments of the polypeptides of (a), (b) or (c) which are biologically active.
- 27. The protein according to claim 26, having an amino acid sequence at least about 80% identical to SEQ ID NO: 11 or SEQ ID NO:13.
 - 28. The protein according to claim 27, which is a soluble RANKL.
 - 29. The protein according to claim 26, which is a soluble RANKL.
- 30. A soluble RANKL protein which further comprises a peptide selected from the group consisting of an immunoglobulin Fc domain, an immunoglobulin Fc mutein, a FLAGTM tag, a peptide comprising at least about 6 His residues, a leucine zipper, and combinations thereof.
 - 31. An antibody immunoreactive with RANKL polypeptide according to claim 26.
- 25 32. The antibody according to claim \$1, which is a monoclonal antibody.
 - 33. A method of inducing maturation of dendritic cells (DC), comprising contacting CD1a+ DC with an amount of a RANKL polypeptide sufficient to result in decreased levels of CD1b/c expression on the DC, under conditions promoting viability of the DC, and allowing the DC to mature.
 - 34. A method of enhancing allo-stimulatory capacity in dendritic cells (DC), comprising contacting CD1a+ DC with an amount of a RANKL polypeptide sufficient to increase the allo-stimulatory capacity of the DC in a mixed lymphocyte reaction (MLR), under conditions promoting viability of the DC, and allowing the DC to present antigiens to T cells.

IMMUNEX CORPORATION

Docket No. 2852-A

35. A method of promoting viability of T cells in the presence of TGFB, comprising contacting T cells that have been exposed to TGFB with an amount of a RANKL polypeptide sufficient to increase the nuber of T cells that remain viable in the presence of TGFB, under conditions that would promote viability of T cells in the absence of TGFB, and allowing the T cells to influence T cell tolerance.

add Rid

5

GOD SI